Madigan Catherine 4

What Happened

• Catherine Madigan, Chief Medical Officer of Hemab Therapeutics (COAG), was granted derivative equity awards in two transactions: a warrant for 145,134 shares on Jan 29, 2026, and an option for 49,016 shares on Apr 30, 2026. Both grants show $0.00 per share (awarded rather than purchased), totaling 194,150 underlying shares. These are awards/option grants (transaction code A), not sales or open-market purchases.

Key Details

• Transaction dates and prices:
  • Jan 29, 2026: Warrant for 145,134 shares, $0.00 per share (Footnote F1).
  • Apr 30, 2026: Option for 49,016 shares, $0.00 per share (Footnote F2).
• Vesting:
  • Jan 29 warrant vests over four years: 25% on Jan 1, 2027, then equal monthly installments thereafter (F1).
  • Apr 30 option vests over four years in equal monthly installments from May 1, 2026 through May 1, 2030 (F2).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: The Form 4 was filed May 4, 2026. The Jan 29 grant was reported well after the two-business-day Form 4 deadline (and the Apr 30 grant was also reported more than two business days later), so these filings appear late.
• Nature of award: These are derivative grants (warrant and option) that create the right to acquire shares subject to vesting — no underlying shares were reported as immediately issued or sold.

Context

• These awards are compensation-related grants, not purchases; they reflect potential future ownership if vesting and any exercise conditions are met. They do not indicate any immediate sale or cash proceeds by the insider. For retail investors, vesting schedules and future stock price will determine any eventual value; awards granted at $0 simply mean the insider did not pay cash for the grant at issuance.